Teva Pharmaceutical Industries Limited (TEVA) Announces FDA Acceptance Of sNDA Filing For Pediatric Indication for QNASL® (Beclomethasone Dipropionate) Nasal Aerosol
5/13/2014 8:53:25 AM
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental new drug application (sNDA) for a lower dose QNASL® (beclomethasone dipropionate) Nasal Aerosol for the treatment of seasonal and perennial allergic rhinitis in children 4-11 years of age. QNASL is a waterless intranasal corticosteroid spray currently available for the treatment of nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in patients 12 years of age and older.
Help employers find you! Check out all the jobs and post your resume.
comments powered by